RNA-based cancer vaccines

Development of personalized RNA-based cancer vaccines. Tumor samples are subjected to whole genome sequencing and genetic mutations related to immunogenic feature will be screened out for the design of RNA-based vaccines. RNAs encoding for unique tumor antigens could be either injected to human body or transfected into DCs to develop cell surface antigens. RNAs will express antigenic protein in the APCs and present specific antigens through MHC I and MHC II. Presentation of antigens by APCs will promote the interactions between APCs and immune system cells, through the interactions of antigens and T cell receptors. This interaction will trigger a series of downstream immune responses.